Natera announces expansion in early cancer detection and screening



AUSTIN, Texas – (COMMERCIAL THREAD) –Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing and diagnostics, today announced its expansion into the early cancer detection (ECD) market to advance the company’s strategic growth goals in emerging areas of cancer. ECD and screening. Alexey Aleshin, MD, MBA, has been appointed Managing Director (GM) of ECD, where he will be responsible for the strategy and execution of Natera’s ECD products. Dr Aleshin previously held leadership positions overseeing Natera’s oncology medical affairs and will continue to hold this position while Natera seeks a Chief Oncology Physician.

“In just a few short years, Natera has grown from a market leader in non-invasive prenatal testing to a leader in molecular residual disease (MRD). We now have an incredible opportunity to transform the health of millions of people by detecting cancer in its early stages, when it can still be treated and potentially curable, ”said Steve Chapman, CEO of Natera. “We are delighted to elevate and welcome Dr. Aleshin, a trusted and proven leader and innovator in oncology, to our leadership team and look forward to benefiting from his clinical expertise and strategic vision at during this crucial stage in the company’s growth.

In November 2021, Natera announced Aarhus University’s exclusive access to a biobank containing up to 40,000 colorectal cancer screening samples prospectively collected for the development and validation of Natera’s EPD products. This largest known sample database of its kind can help accelerate the introduction of Natera’s ECD products to market and potentially support key business milestones, including the launch of a lab-developed test. and FDA approval.

“It has been a pleasure working on the development and commercialization of Signatera â„¢ over the past few years. I am grateful and proud of the work we have done in advancing the field of MRD testing to this day, and look forward to the continued success of our MRD initiatives, ”said Dr Aleshin . “It’s a very exciting time for us at Natera as we start to step up in the ECD, and I’m honored to lead this incredibly talented team. Our partnership with Aarhus University, coupled with our own early stage genomic data, positions us well to develop innovative DPE products that have the potential to save many lives.

Dr Aleshin joined Natera in 2017 as Medical Director of Oncology and most recently served as Vice President of Oncology Medical Affairs. Prior to Natera, Dr. Aleshin was actively involved as an advisor and consultant in various companies focused on advancing the clinical adoption of next generation sequencing technologies. He received his MD and MBA from UCLA, then completed his residency at Stanford University Medical Center and his hematology / oncology fellowship at Stanford Hospital, where his research focused on genomic profiling. comprehensive, single-cell sequencing and new MRD technologies.

About Natera

Natera â„¢ is a leader in personalized genetic testing and diagnostics, transforming the way we make critical healthcare decisions. Our tests help clinicians and their patients protect their health and enable earlier, more targeted interventions to lead healthier, longer lives. Natera’s tests are validated by over 100 peer-reviewed studies that demonstrate high accuracy and have helped improve oncology patient care outcomes, women’s health, and organ health. Natera operates ISO 13485 certified and CAP accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. For more information visit

Forward-looking statements

All statements other than statements of historical fact contained in this press release are forward-looking statements and do not constitute a representation that Natera’s plans, estimates or expectations will be realized. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update any forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our efforts to develop and market new product offerings, our ability to successfully increase demand, and income from our product. offers, whether the results of clinical or other studies will support the use of our product offerings, our expectations for the reliability, accuracy and performance of our tests, or the benefits of our tests and product offerings for them. patients, providers and payers, or third party payor coverage and reimbursement determinations. Additional risks and uncertainties are discussed in more detail in the “Risk Factors” section in recent documents filed by Natera on Forms 10-K and 10-Q and in other documents that Natera submits from time to time to the DRY. These documents are available on and



Comments are closed.